Novartis CEO sees more restrictive drug pricing to come in US

Speaking to the Financial Times, Joe Jimenez said drug pricing would become more difficult regardless of who wins the U.S. presidential election this fall. 

By Nicole Gray • July 21, 2016

What's so scary about biosimilars?

Biosimilars have been on the market in Europe for years but are just starting to break out in the U.S. Yet some in the medical community remain skeptical, prompting developers to double down on education. 

By Nicole Gray • July 20, 2016

Explore the Trendline➔

Commercialization

New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.

By BioPharma Dive staff

Federal court thwarts AstraZeneca efforts to block Crestor copies

Allergan already markets a generic version of the $5 billion cholesterol drug, but Tuesday's ruling cleared the way for new rivals. 

By Ned Pagliarulo • July 20, 2016

Report: US drug prices often higher than in other developed countries

For example, a month's supply of Gilead's hepatitis C drug Harvoni cost an average of $32,114 in the U.S., but only $22,554 in the U.K. and $18,165 in Spain, according to the report. 

By Edwin Lopez • July 20, 2016

Amgen partners with Daiichi to market biosimilars in Japan

Fresh off winning the backing of an FDA panel for its biosim of Humira, Amgen is readying copycat versions of other big-name biologics. 

By Ned Pagliarulo • July 14, 2016

FDA approves broader use of Pfizer's pneumonia vaccine

Prevnar is now approved for use in adults between the ages of 18 and 49.

By Nicole Gray • July 13, 2016

Increase in US cancer center ad spending fueled by single company

The Cancer Treatment Centers of America accounted for nearly 60% of overall ad money spent by cancer centers in 2014, a JAMA study found. 

By Nicole Gray • July 12, 2016

FDA staff backs Amgen biosim of AbbVie's Humira

An independent advisory panel is set to review Amgen's application early next week. 

By Ned Pagliarulo • July 8, 2016

Pfizer pledges to disclose risks of opioid addiction

In an agreement with the city of Chicago, the drug giant committed to strict standards for marketing and promoting the addictive painkillers. 

By Ned Pagliarulo • July 6, 2016

Federal appeals court reaffirms biosimilar launch rules

The Supreme Court is considering whether to hear a related case on when biosimilar drugmakers must notify brand name companies of their intent to sell copy biologics.

By Ned Pagliarulo • July 5, 2016

Insys stages recovery as FDA approves liquid THC drug

Syndros, Insys' second-approved drug, is still awaiting DEA scheduling however. 

By Edwin Lopez • July 5, 2016

UK cost agency knocks back Bristol-Myers' Opdivo in kidney cancer

In draft guidance, the watchdog raised concerns over the cancer immunotherapy's long term benefit in treating renal cell carcinoma. 

By Ned Pagliarulo • July 5, 2016

Gilead reveals new wave of price hikes for six drugs

Among the six were the HIV drugs Complera and Stribild, along with the blood cancer drug Zydelig. 

By Edwin Lopez • July 5, 2016

Pfizer's PCSK9 drug notches two Phase 3 wins

Bococizumab would be the third PCSK9 drug to hit U.S. markets, but Pfizer hopes to distinguish it with stronger clinical data. 

By Nicole Gray • June 30, 2016

Major trade group slams 'misleading' analysis of drug prices

In an op-ed Wednesday, the president of BIO pushed back on a recent Bloomberg report on rising drug prices, calling it "conjecture." 

By Ned Pagliarulo • June 30, 2016

In narrow vote, FDA panel supports heart benefit claim for Lilly diabetes drug

Allowing Boehringer and Lilly to claim Jardiance cuts the risk of cardiac death is expected to significantly boost the drug's market potential. 

By Ned Pagliarulo • June 29, 2016

What does it take to succeed as a New York biotech startup?

Although biotech has been slow to take off in New York, venture activity in the city may be accelerating. BioPharma Dive spoke with the CEO of Rgenix about why he plans to stay.  

By Nicole Gray • June 29, 2016

Harvard Pilgrim inks pay-for-performance deals with Novartis, Eli Lilly

Outcomes-based pricing has become more common as insurers seek to limit rising prescription drug costs. 

By Ned Pagliarulo • June 28, 2016

Gilead wins FDA nod for pan-genotypic Hep C drug

In an unusual move, Gilead priced Epclusa below the cost of existing drugs Harvoni and Sovaldi, at just under $75,000 for a 12-week course of treatment. 

By Ned Pagliarulo • June 28, 2016

Teva seals deal to market copy of AstraZeneca diabetes drug

Under settlement terms, the Israeli drugmaker will be able to sell generic versions of AstraZeneca's Byetta next year. 

By Ned Pagliarulo • June 24, 2016

Opko wins approval for kidney drug after manufacturing snag

The FDA had turned down Opko's original application due to manufacturing issues at third-party contractor Catalent. 

By Nicole Gray • June 23, 2016

Russian biosims company accuses Roche of undercutting its business

Filing suit in a New York federal court, Biocad claimed Roche tried to block it from entering the U.S. market with biosimilar versions of three Roche cancer drugs.

By Nicole Gray • June 23, 2016

AstraZeneca writes off $80 million after US authorities say nasal flu vaccine ineffective

An advisory panel at the Centers for Disease Control and Prevention recommended against using AstraZeneca's FluMist nasal spray for the upcoming flu season. 

By Ned Pagliarulo • June 23, 2016

Doctors who ate on pharma's dime prescribed drugs more often, study finds

Higher rates of prescribing were seen even though the average meal cost less than $20. 

By Nicole Gray • June 22, 2016

Supreme Court asks for DOJ input on biosimilar case, delaying decision

Novartis' generics unit Sandoz is locked in a legal battle with Amgen over when biosimilars companies can launch copies of branded drugs. 

By Nicole Gray • June 22, 2016